Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bhaskar Dasgupta

Showing results (141-150 of 204) with videos related to

Pageof 21
Sort By:
Rheumatology (Oxford, England)|December 19, 2019
The impact of disease extent and severity detected by quantitative ultrasound analysis in the diagnosis and outcome of giant cell arteritisSara Monti, Cristina Ponte, Claudio Pereira, et al.
The Lancet. Rheumatology|January 27, 2024
Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trialJohn H Stone, Jian Han, Martin Aringer, et al.
Seminars in Arthritis and Rheumatism|December 22, 2016
Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trialKatie Tuckwell, Neil Collinson, Sophie Dimonaco, et al.
Nature Reviews. Rheumatology|June 12, 2023
Disease stratification in GCA and PMR: state of the art and future perspectivesAlessandro Tomelleri, Kornelis S M van der Geest, Muhammad Asim Khurshid, et al.
Rheumatology (Oxford, England)|April 8, 2010
BSR and BHPR guidelines for the management of giant cell arteritisBhaskar Dasgupta, Frances A Borg, Nada Hassan, et al.
The Lancet. Rheumatology|March 30, 2024
Development of a diagnostic prediction model for giant cell arteritis by sequential application of Southend Giant Cell Arteritis Probability Score and ultrasonography: a prospective multicentre studyAlwin Sebastian, Kornelis S M van der Geest, Alessandro Tomelleri, et al.
Annals of the Rheumatic Diseases|June 7, 2013
Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE studyBernard Combe, Bhaskar Dasgupta, Ingrid Louw, et al.
Rheumatology (Oxford, England)|May 13, 2020
Early variation of ultrasound halo sign with treatment and relation with clinical features in patients with giant cell arteritisCristina Ponte, Ana Sofia Serafim, Sara Monti, et al.
Arthritis Care & Research|May 20, 2014
Patient and physician expectations of add-on treatment with golimumab for rheumatoid arthritis: relationships between expectations and clinical and quality of life outcomesBhaskar Dasgupta, Bernard Combe, Ingrid Louw, et al.
BMJ Open|September 8, 2017
Feasibility randomised multicentre, double-blind, double-dummy controlled trial of anakinra, an interleukin-1 receptor antagonist versus intramuscular methylprednisolone for acute gout attacks in patients with chronic kidney disease (ASGARD): protocol studyGowrie Balasubramaniam, Trisha Parker, David Turner, et al.
Pageof 21

Showing results (141-150 of 204) with videos related to

Sort By:
Pageof 21
Rheumatology (Oxford, England)|December 19, 2019
The impact of disease extent and severity detected by quantitative ultrasound analysis in the diagnosis and outcome of giant cell arteritisSara Monti, Cristina Ponte, Claudio Pereira, et al.
The Lancet. Rheumatology|January 27, 2024
Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trialJohn H Stone, Jian Han, Martin Aringer, et al.
Seminars in Arthritis and Rheumatism|December 22, 2016
Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trialKatie Tuckwell, Neil Collinson, Sophie Dimonaco, et al.
Nature Reviews. Rheumatology|June 12, 2023
Disease stratification in GCA and PMR: state of the art and future perspectivesAlessandro Tomelleri, Kornelis S M van der Geest, Muhammad Asim Khurshid, et al.
Rheumatology (Oxford, England)|April 8, 2010
BSR and BHPR guidelines for the management of giant cell arteritisBhaskar Dasgupta, Frances A Borg, Nada Hassan, et al.
The Lancet. Rheumatology|March 30, 2024
Development of a diagnostic prediction model for giant cell arteritis by sequential application of Southend Giant Cell Arteritis Probability Score and ultrasonography: a prospective multicentre studyAlwin Sebastian, Kornelis S M van der Geest, Alessandro Tomelleri, et al.
Annals of the Rheumatic Diseases|June 7, 2013
Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE studyBernard Combe, Bhaskar Dasgupta, Ingrid Louw, et al.
Rheumatology (Oxford, England)|May 13, 2020
Early variation of ultrasound halo sign with treatment and relation with clinical features in patients with giant cell arteritisCristina Ponte, Ana Sofia Serafim, Sara Monti, et al.
Arthritis Care & Research|May 20, 2014
Patient and physician expectations of add-on treatment with golimumab for rheumatoid arthritis: relationships between expectations and clinical and quality of life outcomesBhaskar Dasgupta, Bernard Combe, Ingrid Louw, et al.
BMJ Open|September 8, 2017
Feasibility randomised multicentre, double-blind, double-dummy controlled trial of anakinra, an interleukin-1 receptor antagonist versus intramuscular methylprednisolone for acute gout attacks in patients with chronic kidney disease (ASGARD): protocol studyGowrie Balasubramaniam, Trisha Parker, David Turner, et al.
Pageof 21